Plasma Imidazole Propionate Is Positively Correlated with Blood Pressure in Overweight and Obese Humans
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Plasma Imidazole Propionate Is Positively Correlated with Blood Pressure in Overweight and Obese Humans. / van Son, Jamie; Serlie, Mireille J.; Stahlman, Marcus; Backhed, Fredrik; Nieuwdorp, Max; Aron-Wisnewsky, Judith.
In: Nutrients, Vol. 13, No. 8, 2706, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Plasma Imidazole Propionate Is Positively Correlated with Blood Pressure in Overweight and Obese Humans
AU - van Son, Jamie
AU - Serlie, Mireille J.
AU - Stahlman, Marcus
AU - Backhed, Fredrik
AU - Nieuwdorp, Max
AU - Aron-Wisnewsky, Judith
PY - 2021
Y1 - 2021
N2 - Background: The gut microbiota and its metabolites are essential for host health and dysbiosis has been involved in several pathologic conditions such as type 2 diabetes (T2D) and cardiovascular disease (CVD). Recent studies have identified that plasma imidazole propionate (ImP), a microbial-produced metabolite, is increased in patients with prediabetes and T2D. More recently, ImP was found to be significantly increased in patients with overt CVD. Here, we aimed to investigate the association between ImP and CVD risk factors: blood pressure, HDL-cholesterol, LDL-cholesterol and insulin-resistance in overweight and obese subjects without T2D or use of any metabolic diseases-related medication. Methods: Plasma metabolites, including ImP, were determined in 107 male or post-menopausal women with overweight/obesity, but without T2D. Insulin-sensitivity was assessed with the gold standard method: the hyperinsulinemic-euglycemic clamp using the isotope [6,6-H-2(2)] glucose and expressed as glucose rate of disposal (Rd) for peripheral insulin sensitivity and suppression of endogenous glucose production (EGP) for hepatic insulin sensitivity. Results: Partial correlation analysis controlled for BMI and age showed a significant correlation between ImP and diastolic blood pressure (r(s) = 0.285, p = 0.004) and a borderline significance with systolic blood pressure (r(s) = 0.187, p = 0.060); however, systolic and diastolic blood pressure did not correlate with ImP precursor histidine (r(s) = 0.063, p = 0.526 and r = -0.038, p = 0.712, respectively). We did not find a correlation between ImP with LDL-cholesterol or HDL-cholesterol (r(s) = -0.181, p = 0.064 and r(s) = 0.060, p = 0.546, respectively). Furthermore, there was no association between plasma ImP concentrations and Rd and EGP suppression. Conclusion: In this cohort with overweight/obese subjects without T2D, plasma ImP concentrations were positively correlated with diastolic blood pressure but not with insulin-sensitivity.
AB - Background: The gut microbiota and its metabolites are essential for host health and dysbiosis has been involved in several pathologic conditions such as type 2 diabetes (T2D) and cardiovascular disease (CVD). Recent studies have identified that plasma imidazole propionate (ImP), a microbial-produced metabolite, is increased in patients with prediabetes and T2D. More recently, ImP was found to be significantly increased in patients with overt CVD. Here, we aimed to investigate the association between ImP and CVD risk factors: blood pressure, HDL-cholesterol, LDL-cholesterol and insulin-resistance in overweight and obese subjects without T2D or use of any metabolic diseases-related medication. Methods: Plasma metabolites, including ImP, were determined in 107 male or post-menopausal women with overweight/obesity, but without T2D. Insulin-sensitivity was assessed with the gold standard method: the hyperinsulinemic-euglycemic clamp using the isotope [6,6-H-2(2)] glucose and expressed as glucose rate of disposal (Rd) for peripheral insulin sensitivity and suppression of endogenous glucose production (EGP) for hepatic insulin sensitivity. Results: Partial correlation analysis controlled for BMI and age showed a significant correlation between ImP and diastolic blood pressure (r(s) = 0.285, p = 0.004) and a borderline significance with systolic blood pressure (r(s) = 0.187, p = 0.060); however, systolic and diastolic blood pressure did not correlate with ImP precursor histidine (r(s) = 0.063, p = 0.526 and r = -0.038, p = 0.712, respectively). We did not find a correlation between ImP with LDL-cholesterol or HDL-cholesterol (r(s) = -0.181, p = 0.064 and r(s) = 0.060, p = 0.546, respectively). Furthermore, there was no association between plasma ImP concentrations and Rd and EGP suppression. Conclusion: In this cohort with overweight/obese subjects without T2D, plasma ImP concentrations were positively correlated with diastolic blood pressure but not with insulin-sensitivity.
KW - imidazole propionate
KW - cardiovascular disease
KW - insulin resistance
KW - obesity
KW - gut microbiota
KW - hyperinsulinemic-euglycemic clamp
KW - INSULIN-RESISTANCE
KW - METABOLIC SYNDROME
KW - DIABETES-MELLITUS
KW - RISK-FACTORS
KW - HYPERTENSION
KW - GLUCOSE
KW - SENSITIVITY
KW - MICROBIOTA
KW - INSIGHTS
KW - DISEASE
U2 - 10.3390/nu13082706
DO - 10.3390/nu13082706
M3 - Journal article
C2 - 34444866
VL - 13
JO - Nutrients
JF - Nutrients
SN - 2072-6643
IS - 8
M1 - 2706
ER -
ID: 279259187